Search

Displaying results 1691 - 1700 of 7181 in total
  1. Drug

    Diosmin

    go.drugbank.com/drugs/DB08995
    ApprovedInvestigational

    [A232885] Diosmin is a bioflavonoid isolated from various plants or synthesized from [hesperidin]. … Compression and pharmacotherapy are frequently used to manage chronic venous insufficiency, improving circulation and symptoms of venous disease.

    Mixtures: NASynonyms: Diosmetin 7-O-rutinoside
  2. Drug

    Dipyridamole

    go.drugbank.com/drugs/DB00975
    ApprovedInvestigational

    (From AMA Drug Evaluations Annual, 1994, p752) … A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin.

  3. Drug

    Riltozinameran

    go.drugbank.com/drugs/DB17095
    ApprovedInvestigational

    [L43922] It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). … [L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.

  4. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    This approval was based on favorable results obtained from the phase III APPL-PNH and APPOINT-PNH studies, where 82.3% and 77.5% of patients experienced a sustained hemoglobin improvement without transfusions … [A262581] This is of particular importance to PNH, where one of the disease hallmarks is the mutation of the PIGA gene.

  5. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. … On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis.

  6. Drug

    mRNA-1283

    go.drugbank.com/drugs/DB22668
    ApprovedInvestigational

    [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … [L53408] As opposed to previously approved COVID-19 mRNA vaccines, including the original [Moderna COVID-19 Vaccine], mRNA-1283 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-

  7. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    The amino acid sequence of the product is identical to that of endogenous human IGF-1. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

  8. Drug

    Trifluoperazine

    go.drugbank.com/drugs/DB00831
    Approved

    A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.

    Mixtures: Stelabid No 2, Stelabid No 1
  9. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa. … Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

  10. Drug

    Repotrectinib

    go.drugbank.com/drugs/DB16826
    ApprovedInvestigational

    [A262061] Although resistance to multiple TKI has been reported, including [crizotinib], [lorlatinib], [taletrectinib], and [entrectinib], there has been no reported case of repotrectinib resistance. … This approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741]